Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193125-24-244251
Filing Date
2024-10-25
Accepted
2024-10-25 17:50:26
Documents
1
Group Members
FRANK M. SANDSSANDS CAPITAL VENTURES, LLC

Document Format Files

Seq Description Document Type Size
1 SC 13G d840359dsc13g.htm SC 13G 70791
  Complete submission text file 0001193125-24-244251.txt   72546
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Subject) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-92155 | Film No.: 241398010
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O SANDS CAPITAL VENTURES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209
Business Address C/O SANDS CAPITAL VENTURES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209 703-562-4000
Sands Capital Life Sciences Pulse Fund II, L.P. (Filed by) CIK: 0001875620 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9
Type: SC 13G